GlassScriptPhysician profile
Gurpreet Sodhi
NPI 1225264617
$240,789.23
in general payments reported to CMS, 2019-2025
30 companies · $24K in 2025
The $24K reported for 2025 was more than what 86% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,719 · 2020: $1,381 · 2021: $7,856 · 2022: $71K · 2023: $52K · 2024: $83K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Travel and Lodging: $18K · Honoraria: $14K · Food and Beverage: $13K · Consulting Fee: $1,716 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,375.00 |
| Travel and Lodging | $17,675.87 |
| Honoraria | $14,400.00 |
| Food and Beverage | $12,941.47 |
| Consulting Fee | $1,716.00 |
| Education | $105.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48,297.90 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46,207.79 | 2021-2025 | Jardiance |
| Pfizer INC. | $43,132.72 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $35,394.62 | 2019-2025 | Uptravi, Opsumit, Ventavis |
| Abiomed | $28,723.32 | 2019-2025 | Impella |
| Lilly USA, LLC | $18,525.00 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $7,575.76 | 2022-2025 | Wainua, Farxiga |
| Abbott Laboratories | $4,159.63 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Alnylam Pharmaceuticals INC. | $2,921.93 | 2021-2024 | Amvuttra, Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $1,942.98 | 2021-2025 | |
| Akcea Therapeutics, INC. | $770.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $693.65 | 2019-2025 | |
| Atricure, INC. | $365.77 | 2022-2024 | |
| Edwards Lifesciences Corporation | $303.95 | 2019-2024 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $268.11 | 2022-2024 | Winrevair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $222.22 | 2019 | |
| Vifor Pharma, INC. | $208.44 | 2019-2022 | |
| Merit Medical Systems INC | $191.51 | 2025 | Embocath Plus Microcatheter |
| E.R. Squibb & Sons, L.L.C. | $170.94 | 2022-2023 | Camzyos |
| Heartflow, INC. | $144.65 | 2023 | Ffrct |
| Impulse Dynamics (USA) INC. | $136.94 | 2020 | |
| Chiesi USA, INC. | $124.73 | 2021 | |
| Kestra Medical Technology Services, INC. | $106.07 | 2023 | Assure Wcd |
| Inari Medical, INC. | $58.91 | 2020 | |
| Amgen INC. | $51.76 | 2022-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $37.73 | 2019 | |
| Itamar Medical INC | $23.40 | 2022 | |
| United Therapeutics Corporation | $16.02 | 2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $12.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Sodhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.